Patients underwent 18F-FDG PET/CT on a Discovery VCT scanner (GE Medical Systems, Milwaukee, WI, USA). The blood sugar level was <120 mg/dL after at least 6 hours of fasting, and 5.18 MBq/kg of 18F-FDG were administered intravenously in each patient 1 hour before PET/CT scanning. CT scanning was performed at 120 kVp for attenuation correction and to obtain anatomic information. PET scans were obtained from the skull base to the upper thigh level with a 128 × 128 matrix size. The voxel size was 3.91 × 3.91 × 3.27 mm3. Images were reconstructed with an ordered subset expectation maximization iterative algorithm (2 iterations and 8 subsets).
Discovery vct scanner
Manufactured by GE Healthcare
Sourced in United States
The Discovery VCT scanner is a computed tomography (CT) imaging system developed by GE Healthcare. It is designed to capture high-quality, three-dimensional images of the human body for diagnostic purposes. The core function of the Discovery VCT scanner is to acquire and process CT data, enabling healthcare professionals to visualize and analyze the internal structures and organs of patients.
Automatically generated - may contain errors
Lab products found in correlation
Discovery st scanner, by GE Healthcare (3 mentions)
Discovery mi scanner, by GE Healthcare (3 mentions)
Discovery 690 standard scanner, by GE Healthcare (3 mentions)
Vct sixty four row mdct system, by GE Healthcare (2 mentions)
Signa pet mr, by GE Healthcare (1 mentions)
Ingenia, by Philips (1 mentions)
Achieva, by Philips (1 mentions)
Signa hdxt, by GE Healthcare (1 mentions)
Biograph mct flow, by Siemens (1 mentions)
3t signa pet mr scanner, by GE Healthcare (1 mentions)
Discovery 710, by GE Healthcare (1 mentions)
Discovery st, by GE Healthcare (1 mentions)
12 protocols using discovery vct scanner
1
FDG PET/CT Imaging Protocol
2
Standardized FDG-PET/CT and PET/MR Protocols
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
FDG-PET/CT was performed using a Discovery MI scanner (GE Healthcare, Waukesha, WI), Discovery 690 Standard scanner (GE Healthcare), Discovery VCT scanner (GE Healthcare), or Discovery ST scanner (GE Healthcare). FDG-PET/MR was performed using a 3 T PET/MR scanner (Signa PET/MR, GE Healthcare). According to our institution’s protocol, a standardized dose of 3.5 MBq of [18F]FDG per kg body weight (PET/CT) or 3.0 MBq per kg body weight (PET/MR) was injected until 2017, and from 2017 on, BMI-adapted body weight–dependent dosage protocols were used24 (link). The CT included of a standardized protocol of high-resolution axial volume acquisition (0.6–1.0 mm) with reconstructions in the coronal and sagittal plane in the bone and soft tissue kernel with contrast enhancement of the sinonasal and neck region. For the sinonasal and neck MR, dedicated regionalized T2-weighted and T1-weighted pulse sequences with and without gadolinium-based contrast agent and with and without fat suppression were used23 (link).
3
PET/CT Evaluation of Thyroid FDG Uptake
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The PET/CT was performed on a Discovery VCT scanner (GE Healthcare, Waukesha, WI, USA) in accordance with institutional procedures. The mean activity of FDG activity was 370 MBq. Blood glucose levels were less than 11 mmol/L in all patients. The PET/CT was acquired approximately 60 min after tracer injection. The CT scan was performed as low-dose CT or diagnostic CT with contrast-enhancement.
Classification of pathological FDG uptake in the thyroid was based on clinical impression (relative uptake in the thyroid versus background and/or asymmetry) and supported by semi-quantitative analysis of the uptake by calculation of standardized uptake value (SUV). Per institutional practice, all FDG PET/CT scans were read independently by two trained hybrid imaging specialists, in most cases a nuclear medicine physician and a radiologist, and a final diagnosis of pathological FDG uptake was made in consensus. For this study, the CT scans were used exclusively to verify the thyroidal confinement of the FDG-avid lesions.
Classification of pathological FDG uptake in the thyroid was based on clinical impression (relative uptake in the thyroid versus background and/or asymmetry) and supported by semi-quantitative analysis of the uptake by calculation of standardized uptake value (SUV). Per institutional practice, all FDG PET/CT scans were read independently by two trained hybrid imaging specialists, in most cases a nuclear medicine physician and a radiologist, and a final diagnosis of pathological FDG uptake was made in consensus. For this study, the CT scans were used exclusively to verify the thyroidal confinement of the FDG-avid lesions.
4
3D T1-Weighted MRI and 18F-Florbetaben PET Imaging
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
We acquired three-dimensional (3D) T1-weighted MR images in Digital Imaging and Communications in Medicine format using Philips Achieva and Ingenia scanners (Philips Medical Systems, Eindhoven, The Netherlands). The parameters were as follows: voxel dimensions=1.0×0.5×0.5 mm3, slice thickness=1.0 mm, echo time=8.15 or 8.20 ms (for Achieva and Ingenia, respectively), repetition time=4.61 ms, flip angle=8°, and field of view=240×240 mm.
We acquired 18F-florbetaben PET scans in 3D using a Discovery VCT scanner (General Electric Medical Systems, Milwaukee, WI, USA). The subjects were injected with 8.1 mCi (300 MBq) 18F-florbetaben (Neuraceq; Life Molecular Imaging Ltd., Berlin, Germany) through a slow single intravenous bolus (6 MBq) in a total volume of 10 mL. After a 90-min uptake period, 20-min PET images comprising four 5-min dynamic frames were obtained. Images of each time frame were reframed into one summed frame. Board-certified nuclear medicine physicians then determined Aβ-positivity based on visual interpretation of tracer uptake in the gray matter compared to neighboring subcortical white matter in the following four brain regions: the temporal lobes, frontal lobes, posterior cingulate cortex/precuneus, and parietal lobes.
We acquired 18F-florbetaben PET scans in 3D using a Discovery VCT scanner (General Electric Medical Systems, Milwaukee, WI, USA). The subjects were injected with 8.1 mCi (300 MBq) 18F-florbetaben (Neuraceq; Life Molecular Imaging Ltd., Berlin, Germany) through a slow single intravenous bolus (6 MBq) in a total volume of 10 mL. After a 90-min uptake period, 20-min PET images comprising four 5-min dynamic frames were obtained. Images of each time frame were reframed into one summed frame. Board-certified nuclear medicine physicians then determined Aβ-positivity based on visual interpretation of tracer uptake in the gray matter compared to neighboring subcortical white matter in the following four brain regions: the temporal lobes, frontal lobes, posterior cingulate cortex/precuneus, and parietal lobes.
5
FDG PET-CT Imaging Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
18F-FDG PET-CT scans were acquired using a Discovery VCT scanner (GE Medical Systems, Milwaukee, WI, USA). All patients fasted for at least 6 hours prior to the scan and blood sugar levels were confirmed to be <120 mg/dL. 5.18 MBq/kg of 18F-FDG was administered intravenously in each patient 1 hour before PET-CT scanning. CT scans (3 mm slice thickness; tube voltage: 120 kVp; tube current-time product: 50–80 mAs depending on the patient’s weight) were performed to obtain anatomic information. PET scans were obtained from the skull base to the upper thigh level with a 128 × 128 matrix. Images were reconstructed with an ordered subsets expectation maximization iterative algorithm (2 iterations, 8 subsets). The standardized uptake values were calculated using lean body mass.
6
Ga-68 Edotreotide PET/CT Imaging Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All patients underwent [68Ga]Ga-edotreotide PET/CT. The patients received [68Ga]Ga-edotreotide intravenously (median:181; range:148-259 MBq; weight-based). Sixty minutes after the tracer injection, PET and modulated low dose CT were carried out with a PET/CT scanner (GE Discovery VCT scanner; Waukesha, WI) that combined a PET scanner and a Light Speed VCT sixty-four row MDCT system. MDCT (pitchx 1.5; 120 mAs; 120 kVp) was performed without contrast medium. The PET scanning was subsequently performed, acquiring 3 minutes per bed position and 6 to eight beds per patient depending on patient height encompassing the whole skeleton. The raw CT data were reconstructed into transverse images with a 3.75-mm section thickness. Sagittal and coronal CT images was generated by reconstruction of the transverse data. Raw PET data were reconstructed with and without attenuation correction into transverse, sagittal, and coronal images. Attenuation correction was based on CT attenuation coefficients, which were determined by iterative reconstruction.
7
Multimodal Imaging Protocol for Neuroimaging
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The CT images were acquired on a high-resolution Discovery VCT scanner (GE Healthcare®, Waukesha, WI, USA), using a standard, vendor-defined, and contrast enhanced protocol. No metal artifact reduction protocol was used.
All MRI imaging were performed on a 1.5-T magnet Signa HDxt (GE Healthcare®, Waukesha, WI, USA) using a dedicated eight-channel neurovascular (NV) array coil without contrast enhanced protocol (8CTL12, GE Healthcare®). The patient was in a supine position with the head immobilized with foam cushions.
All MRI imaging were performed on a 1.5-T magnet Signa HDxt (GE Healthcare®, Waukesha, WI, USA) using a dedicated eight-channel neurovascular (NV) array coil without contrast enhanced protocol (8CTL12, GE Healthcare®). The patient was in a supine position with the head immobilized with foam cushions.
8
PSMA-PET/CT Imaging Protocols
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
PSMA-PET/CT was performed using a Discovery MI scanner (GE Healthcare, Waukesha, WI), Discovery 690 Standard scanner (GE Healthcare), Discovery VCT scanner (GE Healthcare), Discovery ST scanner (GE Healthcare), or Siemens Biograph mCT Flow (Siemens Healthineers, Munich, Germany). The injected dose was 3–4 MBq/kg for [18F]F-PSMA-1007 and 2–3 MBq/kg for [68Ga]Ga-PSMA-11 at both centers. The maximum injected dose was not more than 350 MBq. The uptake time was 60 min for [68Ga]Ga-PSMA-11 and 90 min for [18F]F-PSMA-1007 at both centers.
9
PET/CT Imaging Protocol for [F-18] FDG
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The patients were well-hydrated before receiving [F-18] FDG intravenously (444–555 MBq). Sixty minutes after the tracer injection, PET and CT scans were obtained using a commercial PET/CT scanner (GE Discovery VCT scanner; Waukesha, WI) that combines a PET scanner and a Light Speed VCT sixty-four row MDCT system. MDCT (pitchx 1.5; 120 mAs; 120 kVp) was performed without the use of an intravenous and/or oral contrast medium. The PET scanning was subsequently performed, acquiring 4 minutes per bed position and six to eight bed positions per patient, depending on patient height. The raw CT data were reconstructed into transverse images with a 3.75-mm section thickness. Sagittal and coronal CT images were generated by reconstruction of the transverse data. Raw PET data were reconstructed with and without attenuation correction into transverse, sagittal, and coronal images. Attenuation correction was based on the CT attenuation coefficients, which were determined by iterative reconstruction. The patients were kept fasting for at least 6 hours prior to the imaging. Blood glucose levels were measured in all patients before [F-18] FDG administration; patients with values above 7.77 mMol/L (140 ml/dl) were excluded from examination.
10
Brain Amyloid PET Imaging Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Brain 18F-florbetaben amyloid PET images were obtained using a Discovery VCT scanner (General Electric Medical Systems; Milwaukee, WI, USA). We injected 8.1 mCi (300 MBq) of 18F-florbetaben (Neuraceq, Piramal, Mumbai, India) as a slow single intravenous bolus (6 s/mL) in a total volume of up to 10 mL and obtained 20-min PET images comprising four 5-min dynamic frames after a 90-min uptake period. Trained radiologists with expertise in nuclear medicine determined amyloid beta peptide (Aβ)-positivity based on the brain amyloid plaque load (BAPL) score. The BAPL score is a predefined three-grade scoring system wherein measurements are made by the physician according to the visual assessment of the participant’s amyloid deposition in the brain using Neuraceq. BAPL scores of 1 (BAPL 1), 2 (BAPL 2), and 3 (BAPL 3) indicate no Aβ load, minor Aβ load, and significant Aβ load, respectively. Therefore, BAPL 1 indicates an Aβ-negative status, whereas BAPL 2 and BAPL 3 indicate an Aβ-positive status27 (link).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!